Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2010. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction notification rather than comprehensive financial performance.
Material Changes
No material changes to financial performance or operations are reported. The filing details a re-valuation of the cash element of the notional investment held within the US Retirement Savings Plan, which is notionally held in GSK Ordinary share ADRs.
Guidance, Outlook, and Risks
Management commentary, guidance, outlook, risks, contingencies, and unusual items are not addressed in this filing. The document strictly reports a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: The notional allocation increase occurred on March 19, 2010.
- Price: The transaction price was $38.57 per ADR.
- Individual Involved: Ms. D Connelly received an increase in the notional allocation of 14 Ordinary share ADRs.
- Notification Date: The Administrators of the Plan notified GlaxoSmithKline plc on March 22, 2010.